Abstracts tagged "ACPA and Periodontitis"

Abstract Number: 61 • 2018 ACR/ARHP Annual Meeting
A Human ACPA Monoclonal Antibody Is Preferably Localized at Inflammatory Gingival Tissue and Activates Osteoclastogenensis in Porphyromonas Gingivalis Infected SKG Mouse
Kazuhisa Ouhara¹, Tatsuhiko Ozawa², Syuichi Munnaga¹, Tatsuomi Kuranobu³, Yuta Hamamoto¹, Toshihisa Kawai⁴, Eiji Sugiyama⁵ and Hidemi Kurihara¹, ¹Periodontal Medicine, Hiroshima University, Hiroshima, Japan, ²Department of Immunology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan, ³Clinical Immunology and Rheumatology, HIroshima University Hospital, Hiroshima, Japan, ⁴Periodontology, Nova Southeastern University College of Dental Medicine, Fort Lauderdale, FL, ⁵Department of Clinical Immunology and Rheumatology, Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan
Background/Purpose: Periodontal disease (PD) is the chronic inflammatory disease caused by the infection of periodontopathogenic bacteria, Porphyromonas gingivalis (Pg). Pg infection is known as major…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.